2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 486

Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
Abstract Number: 487

Early Rheumatoid Arthritis Patients in the Worse Disease Trajectory Group Fail to Achieve Improvement in Physical Function
Abstract Number: 488

Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Abstract Number: 489

Drug Survival and Toxicity of Methotrexate Monotherapy in Daily Clinical Practice. Results from an Early Arthritis Clinic
Abstract Number: 490

Personalizing the Treat to Target Approach in Rheumatoid Arthritis
Abstract Number: 491

A Paradigm Shift in the Disease Assessment of Rheumatoid Arthritis : From Blood to Urine Testing
Abstract Number: 492

Correlations Between Clinical, Laboratory and Ultrasound Joint Examination in RA Patients Treated with Rituximab
Abstract Number: 493

Diagnostic Delay in Early Arthritis: Ten Years-Experience of a Single Center
Abstract Number: 494

High C-Reactive Protein at Baseline Is Associated with Long-Term Treatment Persistence in Patients with Rheumatoid Arthritis Treated with Rituximab
Abstract Number: 495

Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy
Abstract Number: 496

Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate
Abstract Number: 497

Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
Abstract Number: 498

Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Abstract Number: 499

Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Abstract Number: 500

Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].